Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
BiOM has named Dr. Charles Carignan as its next CEO, replacing Tim McCarthy, who left the company this past spring.
Carignan is a 20-year medtech veteran who has held several key positions in the medical device industry, including most recently at NinePoint Medical, where he was the founder and CEO. Read more
Boston Scientific reportedly put down a $15 million investment in Israeli heart valve developer Mvalve Technologies that includes a $200 million buyout option.
Mvalve is developing technology to treat mitral valve regurgitation, according to its LinkedIn profile. Co-founder & CEO Assif Stoffman is an executive vice president with Israeli venture capital fund XT Hitech, which is the sole investor in Mvalve, according to Globes. Read more
Biomet said last week that the U.S. Securities & Exchange Commission issued a subpoena over alleged “improprieties” by Biomet employees in Brazil and Mexico, more than 2 years after the medical device company settled similar allegations with the SEC and the U.S. Justice Dept. for more than $22 million.
Warsaw, Ind.-based Biomet said July 3 that it “became aware of certain alleged improprieties regarding its operations in Brazil and Mexico” in October 2013 and retained lawyers and “other experts” to investigate. Read more